ISSN:
1569-8041
Keywords:
chemotherapy
;
cisplatin
;
doxorubicin
;
mitomycin
;
molgramostim
;
sarcoma
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background: A phase I study was designed for the amalgamation of twopreviously studied antisarcoma regimens (ifosfamide + doxorubicin andmitomycin + doxorubicin + cisplatin) supported by molgramostim. Thus, we hopedto develop a better regimen for the treatment of advanced sarcomas. Patients and methods: Fifteen adult advanced sarcoma patients and six otherpatients were registered and sequentially assigned to receive threeprogressively more myelosuppressive levels of chemotherapy: level I –ifosfamide 2500 mg/m2 + doxorubicin 40 mg/m2+ cisplatin 60 mg/m2 all given on day 0, followed bymolgramostim 5 µg/kg every 12 hours for 14 days; level II –exactly the same chemotherapy from level I given on day 1 preceded on day 0by ifosfamide 2500 mg/m2 and an additional four days ofmolgramostim given on days −6 through −3; level III – sameas level II except for the addition of mitomycin 4 mg/m2immediately prior to cisplatin on day 1. MESNA 500 mg/m2 wasgiven five times on each day that involved ifosfamide treatment. For alllevels, treatment was repeated at four-week intervals. Results: Preliminary results and toxicity were reported three years ago (JNatl Cancer Inst 86: 312–4, 1994). Mature results confirm theseunexpectedly favorable results with five advanced sarcoma patients stillsurviving after more than three years (four more than four years). Hypothesis: Molgramostim given subcutaneously in a relatively intensiveschedule might enhance the antitumor effects initiated by cytotoxic drugs inpatients with advanced sarcomas. This idea should be tested formally in phaseIII studies.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008292010062
Permalink
